Clinical Trial Update: Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating durvalumab given with chemoradiation in patients with unresectable non-small cell lung cancer. Results were posted on 2025-01-07.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-07